D. W. Kim - Yonsei University | 人才画像

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 1024 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

11P Patritumab Deruxtecan (Her3-Dxd) in Previously Treated Patients (pts) with Advanced EGFR-mutated (egfrm) NSCLC: Updated Safety Results from HERTHENA-Lung01

H. Hayashi,Y. Goto,H.A. Yu,P.A. Jänne,J.C-H. Yang,M. Reck,K. Yoh, S-H. Lee,L. Paz-Ares,B. Besse,P. Bironzo,D-W. Kim,Z. Piotrowska,M.L. Johnson, A. Sporchia, K.H. Sullivan,Q. Dong,P. Shrestha, J. Shah,E. Felip

ESMO Open (2024): 102590-102590

引用0浏览0引用

Headache As an Aura in Patients with Focal and Generalized Seizures

D. W. Kim, D. W. Kwack

JOURNAL OF HEADACHE AND PAIN (2024)

引用0浏览0引用

1279P First-line Lorlatinib Vs Crizotinib in Asian Patients with ALK+ Non-Small Cell Lung Cancer (NSCLC): 5-Year Outcomes from the CROWN Study

Y-L. Wu,H.R. Kim,R.A. Soo,Q. Zhou, H. Akamatsu,G-C. Chang,C.H. Chiu, H. Hayashi,S-W. Kim,Y. Goto, T. Kato, J. Zhou,V.H.F. Lee, M. Nishio,B. Han,D-W. Kim, S. Lu,A. Polli,J-F. Martini,T.S.K. Mok

Annals of Oncology (2024): S815-S817

引用0浏览0引用

Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (Her3-Dxd) in EGFR-mutated NSCLC

H. A. Yu,C. Baik,D. -W. Kim,M. L. Johnson,H. Hayashi,M. Nishio,J. C. -H. Yang,W. -C. Su,K. A. Gold,M. Koczywas,E. F. Smit,C. E. Steuer,E. Felip,H. Murakami,S. -W. Kim, X. Su, S. Sato,P. -D. Fan, M. Fujimura, Y. Tanaka,P. Patel,D. W. Sternberg,D. Sellami,P. A. Jaenne

ANNALS OF ONCOLOGYno. 5 (2024): 437-447

引用1浏览0WOS引用

638P Dacomitinib with or Without Dose Titration in Treatment Naïve Advanced EGFR Mutated NSCLC: Primary Analysis of the ATORG-003 Phase II Trial

A.C. Tan,T.M. Kim, S. Zhou, L. Yueh Ni,G.F. Ho,L.M. Tho,T. Reungwetwattana,N. Prasongsook,S. Lee, S.H. Tan,D-W. Kim,T.S.K. Mok,D.S.W. Tan,H.H.F. Loong

Annals of Oncology (2024): S1641

引用0浏览0引用

Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study

A. C. Tan,A. O. L. Seet,D. -W. Kim,G. F. Ho, J. Ho,B. -C. Liao,L. M. Tho, A. R. Ahmad,T. Reungwetwattana,Y. Goto,N. Sandhir, S. S. Hsing,D. H. Lee,H. Loong,D. S. W. Tan

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S352-S353

引用0浏览0引用

1319MO Intracranial Efficacy of HER3-DXd in Patients with Previously Treated Advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

M.L. Johnson,P.A. Jänne,Y. Goto,K. Yoh, S-H. Lee,L. Paz-Ares,B. Besse,S. Novello,H. Hayashi,D-W. Kim,T. John,S.C-H. Kao,E. Felip,J.C-H. Yang,M. Reck,Q. Dong, A. Sporchia,D.W. Sternberg,H.A. Yu

Annals of Oncology (2023): S760-S761

引用0浏览0引用

Évaluation De La Résistance Acquise Au Sotorasib Dans Le Cancer Colorectal (CCR) Et Le Cancer Bronchique Non À Petites Cellules (CBNPC) Avec Mutation KRASG12C : Analyse De Biomarqueurs Plasmatiques De L’étude CodeBreaK 100

J. Mazières,B.T. Li,V. Velcheti,T.J. Price,D.S. Hong,M. Fakih,D.W. Kim,G.S. Falchook, J.P. Delord,G.K. Dy,S.S. Ramalingam,J.H. Strickler,T. Kurata,J. Wolf, A.G. Sacher,A. Addeo,H. Prenen,A. Hindoyan,A. Anderson,A. Ang

Revue des Maladies Respiratoires Actualitésno. 1 (2023): 131

引用0浏览0引用

PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib Vs Crizotinib in ALTA-1L

Journal of Thoracic Oncologyno. 3 (2023): e27

引用0浏览0引用

1348P Management of Paresthesia in Patients Treated with Lazertinib: Integrated Analysis of LASER201 and LASER301 Studies

Y-G. Lee,J. S. Ahn,M-J. Ahn,J. H. Kang,R. A. Soo,T. Reungwetwattana,J. C-H. Yang,I. Cicin,D-W. Kim,B. Zaric,H. Go, K. C. Jahng,S. Kim,Y. Lim,K. H. Lee,B. C. Cho

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn